DIAGNOS Appoints Dr. Ismail Ben Ayed as Chief Artificial Intelligence (AI) Scientist to Accelerate our Innovation in Healthcare
MWN-AI** Summary
Diagnos Inc. (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Canadian leader in artificial intelligence (AI) for early detection of eye-related health issues, has appointed Dr. Ismail Ben Ayed as its Chief Artificial Intelligence Scientist. Announced on December 16, 2025, this strategic decision aims to enhance the development and effectiveness of Diagnos' innovative CARA (Computer-Assisted Retinal Analysis) platform.
Dr. Ben Ayed brings a wealth of expertise in medical imaging algorithms, machine learning, and computer vision, having served as a full-time professor at École de Technologie Supérieure (ÉTS) in Montreal and co-director of the LIVIA research center. His previous experience includes a position as a research scientist at GE Healthcare and an impressive portfolio of over 150 peer-reviewed publications in his field.
In his new role, Dr. Ben Ayed will drive advancements in the accuracy, efficiency, and clinical applications of AI solutions for detecting eye diseases. He is tasked with leading the design of next-generation visual AI tools for the CARA System and expanding Diagnos' in-house AI team. Additionally, he will establish critical academic and industry collaborations to aid in the development and validation of clinical AI applications.
André Larente, the president of Diagnos, expressed excitement over Dr. Ben Ayed’s appointment, emphasizing the alignment of his skills with the company’s mission to use AI to improve global patient outcomes. Dr. Ben Ayed added that he looks forward to enhancing the accessibility of cutting-edge AI technology for early detection of retinal diseases, aiming to create scalable, validated AI models that can revolutionize preventative care.
Diagnos continues to be dedicated to improving diagnostic accuracy and patient care through advanced AI technology. For more information, visit www.diagnos.com.
MWN-AI** Analysis
DIAGNOS Inc. (TSX Venture: ADK) is making strategic moves that could position it favorably in the burgeoning field of AI-driven healthcare solutions, specifically for eye health. The appointment of Dr. Ismail Ben Ayed as Chief AI Scientist marks a significant step in enhancing the company's data-driven medical technology. With Dr. Ben Ayed’s profound expertise in medical imaging and machine learning, DIAGNOS is set to bolster its CARA (Computer-Assisted Retinal Analysis) platform and expand its capabilities in detecting eye-related diseases.
For investors, this development presents a valuable opportunity. The integration of advanced AI solutions into healthcare is not just a trend; it is rapidly becoming a necessity as the industry seeks to improve diagnostic accuracy and efficiency—an imperative highlighted by the growing global aging population and the prevalence of eye diseases. Dr. Ben Ayed’s commitment to developing robust AI tools reflects a forward-thinking approach that could lead to significant market differentiation for DIAGNOS.
Furthermore, his emphasis on establishing academic and industry partnerships indicates an intention to enhance credibility and expedite technology validation, which are crucial for scaling operations. This could also attract attention from larger healthcare systems and potential investors, further increasing DIAGNOS’s market presence.
While the announcement carries a positive outlook, investors should remain aware of the inherent risks associated with innovation in the healthcare sector, particularly concerning regulatory hurdles and market competition. Nevertheless, considering the current market trends favoring AI in healthcare, DIAGNOS appears to be well-positioned for growth.
In conclusion, those interested in healthcare technology may find that DIAGNOS's focus on AI-driven early detection systems offers compelling investment opportunities, especially as Dr. Ben Ayed embarks on his mandate to accelerate innovation and enhance patient outcomes on a global scale.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BROSSARD, Quebec, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in applying techniques in Artificial Intelligence (AI) for the early detection of eye-related health issues, is pleased to announce the appointment of Dr . Ismail Ben Ayed, as Chief Artificial Intelligence (AI) Scientist .
Mr. Ben Ayed is an expert in medical image analysis algorithms, machine learning and computer vision. Mr. Ben Ayed will guide the Company’s strategic direction in AI research and development. His mandate includes advancing the accuracy, efficiency, and clinical utility of DIAGNOS’ proprietary CARA (Computer-Assisted Retinal Analysis) System platform and expanding AI capabilities to support detection of eye related diseases.
A recognized leader in AI for Medical Imaging
Dr. Ben Ayed is a full-time Professor at the Department of System Engineering at École de Technologie Supérieure (ÉTS) in Montreal and co-director of the LIVIA (Laboratoire d’Imagerie, Vision et Intelligence Artificielle) research center. Before joining the ETS in 2015, he worked as a research scientist at GE Healthcare. He has an extensive publication record including over 150 peer-reviewed articles.
“We are thrilled to welcome Ismail to our leadership team,” said André Larente, president of DIAGNOS . “His experience in deep learning and medical imaging aligns perfectly with our mission to leverage AI to improve patient outcomes globally.
Future vision for DIAGNOS
In his role, Mr. Ben Ayed will focus on:
- Driving the development of the next-generation Visual AI tools powering CARA System and future DIAGNOS innovations
- Advising and expanding the Company’s in-house AI and Scientific team
- Establishing and strengthening academic and industry partnerships to accelerate development and validation of clinical AI solutions
“I have long followed DIAGNOS’ commitment to making cutting-edge AI accessible for the early detection of retinal diseases,” said Dr. Ben Ayed . My focus will be on accelerating the development of robust, generalizable, and clinically validated AI models that can scale globally and truly transform preventative care.”
About DIAGNOS
DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging Artificial Intelligence, DIAGNOS aims to provide more information to healthcare clinicians to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes on a global scale.
Additional information is available at www.diagnos.com and www.sedarplus.com .
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact:Mr. André Larente, PresidentDIAGNOS Inc.Tel: 450-678-8882 ext. 224alarente@diagnos.ca
FAQ**
What specific advancements in the CARA System does Dr. Ismail Ben Ayed plan to implement to enhance its clinical utility and accuracy within Diagnos Inc. ADK:CC?
How does Diagnos Inc. ADK:CC intend to measure the success and impact of the AI research initiatives led by Dr. Ben Ayed on early detection of eye-related diseases?
What strategies will Diagnos Inc. ADK:CC employ to foster academic and industry partnerships in order to expedite the development of AI solutions for clinical validation?
Can you provide insights on how Dr. Ben Ayed's appointment as Chief AI Scientist will shape the long-term vision and innovation trajectory of Diagnos Inc. ADK:CC in the field of medical imaging?
**MWN-AI FAQ is based on asking OpenAI questions about Diagnos Inc. (OTC: DGNOF).
NASDAQ: DGNOF
DGNOF Trading
0.9% G/L:
$0.2244 Last:
17,490 Volume:
$0.22439 Open:
